Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

METABOLIC DISEASES

Gutting out Myc to decrease ceramides

MYC is a transcription factor controlling growth and nutrient metabolism. Luo et al. now link intestinal expression of MYC to impairments in glucose, lipid and body-weight homeostasis by uncovering novel roles of MYC in regulating the glucagon-like peptide GLP1 and the ceramide-biosynthesis regulator CERS4. Myc deletion in the intestinal epithelium prevents or reverses diet-induced obesity and hepatic steatosis in mice. Critically, people with obesity display elevated MYC and CERS4 expression in the ileum, thus further supporting the clinical relevance of these findings.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: By regulating CerS4 transcription, intestinal MYC controls a gut–liver ceramide axis that regulates hepatic health, body weight and glucose homeostasis.

References

  1. Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A. & Holland, W. L. Nat. Rev. Cardiol. 45, 101145 (2021).

    Google Scholar 

  2. Xia, J. Y. et al. Cell Metab. 22, 266–278 (2015).

    Article  CAS  Google Scholar 

  3. Holland, W. L. et al. Mol. Metab. 6, 267–275 (2017).

    Article  CAS  Google Scholar 

  4. Luo, Y. et al. Nat. Metab. https://doi.org/10.1038/s42255-021-00421-8 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Holland, W. L. et al. Cell Metab. 5, 167–179 (2007).

    Article  CAS  Google Scholar 

  6. Jiang, C. et al. J. Clin. Invest. 125, 386–402 (2015).

    Article  Google Scholar 

  7. Jiang, C. et al. Nat. Commun. 6, 10166 (2015).

    Article  CAS  Google Scholar 

  8. Xie, C. et al. Diabetes 66, 613–626 (2017).

    Article  CAS  Google Scholar 

  9. Xie, C. et al. Nat. Med. 23, 1298–1308 (2017).

    Article  CAS  Google Scholar 

  10. Chaurasia, B. et al. Mol. Metab. 45, 101145 (2021).

    Article  CAS  Google Scholar 

  11. Li, Z. et al. Cell Death Dis. 9, 173 (2018).

    Article  Google Scholar 

Download references

Acknowledgements

The authors received research support from the US National Institutes of Health (DK115824, DK116888 and DK116450 to S.A.S.; DK112826 to W.L.H.), the Juvenile Diabetes Research Foundation (JDRF 3-SRA-2019-768-A-B to S.A.S.), the American Diabetes Association (to S.A.S.), the American Heart Association (to S.A.S.) and the Margolis Foundation (to S.A.S.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William L. Holland.

Ethics declarations

Competing interests

S.A.S. is a consultant, co-founder and shareholder of Centaurus Therapeutics. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Summers, S.A. & Holland, W.L. Gutting out Myc to decrease ceramides. Nat Metab 3, 890–891 (2021). https://doi.org/10.1038/s42255-021-00418-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-021-00418-3

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing